JK06

Asset

Targets 5T4-expressing tumor cells to deliver a cytotoxic drug payload.

Stage
Phase 2
Modality
Other
Target
Not known
4
Indications
1
Trial
2
Developers

Trial NCT06667960 is still running. Named in the news on Oct 23, 2026. businesswire.com

Indications

4

1 more

In the full profile

  • Owner and partners2
  • Trials1
  • Competitors12

Every asset’s record: target, stage, trials and the evidence behind it.

See Pro

Assets